Treatment with tavapadon provided significant improvements in patient experiences of tremor (Part II) relative to placebo. In TEMPO-2 (N=304), tavapadon improved tremor scores by 32% at Week 26 versus 6% with placebo (least squares mean [LSM] change from baseline: placebo, 0.0; 5-15 mg tavapadon, −0.4; LSM difference from placebo [95% CI], −0.3 [−0.5, −0.2]; P<0.0001). Of TEMPO-2 participants who experienced baseline impairment due to tremor (ie, score ≥1), ≥1-point improvements at Week 26 were reported in 45.2% of the tavapadon group and 23.3% of the placebo group, with symptom resolution (ie, score of 0) in 26.2% and 7.5% of tavapadon and placebo-treated participants, respectively. Similar trends were observed in TEMPO-1 (N=529). Most clinician-assessed tremor items (Part III) were significantly improved relative to placebo (TEMPO-1: 5/10 items; TEMPO-2: 7/10 items); items that did not reach significance generally had low baseline scores (ie, median score of 0 or 1).